Eric D. Jacobsen
YOU?
Author Swipe
View article: A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma Open
Synchronous systemic and de novo secondary central nervous system (CNS) large B-cell lymphoma (LBCL) is an aggressive clinical entity with a historically poor prognosis. Given the rarity of this presentation, prospective studies are limite…
View article: Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug–Drug Interaction Study in Patients With Non‐Hodgkin Lymphoma
Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug–Drug Interaction Study in Patients With Non‐Hodgkin Lymphoma Open
Valemetostat tosylate (valemetostat) is an oral, potent, dual inhibitor of enhancer of zeste homolog (EZH)2/1, under investigation in non‐Hodgkin lymphomas (NHLs) and solid tumors. In vitro, it inhibits cytochrome P450 3A (CYP3A) and P‐gly…
View article: Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade
Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade Open
View article: Influence of Rolfing Structural Integration on Lower Limb Mobility, Respiratory Thorax Mobility, and Trunk Symmetry: A Retrospective Cohort Study
Influence of Rolfing Structural Integration on Lower Limb Mobility, Respiratory Thorax Mobility, and Trunk Symmetry: A Retrospective Cohort Study Open
Background: Previous research highlights the potential of Rolfing structural integration (SI)—a force-based mobilization of fascia—in modifying postural alignment and joint mobility. This retrospective cohort study builds upon prior work t…
View article: Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas
Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas Open
Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) require lineage-specific therapies to bridge to hematopoietic stem cell transplantation (HSCT). A previous phase 1/2 study of duvelisib/romidepsin (duv/romi) rep…
View article: Influence of Rolfing Structural Integration on Lower Limb Mobility, Respiratory Thorax Mobility, and Trunk Symmetry: A Retrospective Cohort Study
Influence of Rolfing Structural Integration on Lower Limb Mobility, Respiratory Thorax Mobility, and Trunk Symmetry: A Retrospective Cohort Study Open
Background: Previous research highlights the potential of Rolfing structural integration (SI) - a force-based mobilization of fascia - in modifying postural alignment and joint mobility. This retrospective cohort study builds upon prior wo…
View article: 227 | RITUXIMAB AND EPCORITAMAB AS FIRST‐LINE THERAPY FOR PATIENTS WITH HIGH‐TUMOR BURDEN FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIAL
227 | RITUXIMAB AND EPCORITAMAB AS FIRST‐LINE THERAPY FOR PATIENTS WITH HIGH‐TUMOR BURDEN FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIAL Open
View article: 166 | LACUTAMAB IN PATIENTS WITH RELAPSED AND REFRACTORY SéZARY SYNDROME: LONG TERM FOLLOW‐UP FROM THE TELLOMAK PHASE 2 TRIAL
166 | LACUTAMAB IN PATIENTS WITH RELAPSED AND REFRACTORY SéZARY SYNDROME: LONG TERM FOLLOW‐UP FROM THE TELLOMAK PHASE 2 TRIAL Open
View article: 74 | A MULTICENTER PHASE II STUDY OF GLOFITAMAB PLUS POLATUZUMAB‐R‐CHP FOR PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA
74 | A MULTICENTER PHASE II STUDY OF GLOFITAMAB PLUS POLATUZUMAB‐R‐CHP FOR PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA Open
View article: Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia Open
We analyzed the characteristics and outcomes of 95 patients with chronic lymphocytic leukemia (CLL) after Bruton tyrosine kinase inhibitor (BTKi) and B-cell lymphoma 2 inhibitor (BCL2i) failure. To clearly distinguish sensitivity and resis…
View article: Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial Open
View article: A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma Open
Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are anti-CD19 chimeric antigen receptor (CAR) T-cell therapies approved for relapsed and refractory large B-cell lymphoma (LBCL); however, there is currently no publ…
View article: Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium Open
Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural killer–cell lymphomas (MTCL and MN…
View article: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial Open
View article: Supplementary Data 1 from KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes
Supplementary Data 1 from KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes Open
Supplementary Methods and Figures
View article: Data from KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes
Data from KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes Open
Purpose:Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms.Experimental Design:Primary specimens, cell lines, patient-derived xenograft models, commercially available, and proprietary ant…
View article: Supplementary Data 1 from KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes
Supplementary Data 1 from KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes Open
Supplementary Methods and Figures
View article: Data from KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes
Data from KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes Open
Purpose:Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms.Experimental Design:Primary specimens, cell lines, patient-derived xenograft models, commercially available, and proprietary ant…
View article: Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP
Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP Open
STOP-CA was a multicenter, double-blind, randomized, placebo-controlled trial comparing atorvastatin to placebo in treatment-naïve lymphoma patients receiving anthracycline-based chemotherapy. We performed a preplanned subgroup to analyze …
View article: KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes Open
Purpose: Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms. Experimental Design: Primary specimens, cell lines, patient-derived xenograft models, commercially available, and proprietary …
View article: Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study Open
AbbVie is
View article: Integration of Machine-Learning Approaches to Estimate Survival for Patients with Mature T-Cell and NK-Cell Lymphomas
Integration of Machine-Learning Approaches to Estimate Survival for Patients with Mature T-Cell and NK-Cell Lymphomas Open
View article: POSTER: TCL-054 A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-Cell Lymphoma: Impact of Autologous Stem Cell Transplant (ASCT)
POSTER: TCL-054 A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-Cell Lymphoma: Impact of Autologous Stem Cell Transplant (ASCT) Open
View article: POSTER: TCL-423 The Outcomes of Patients With T-Cell Prolymphocytic Leukemia After Allogenic Stem Cell Transplant: A Multicenter Retrospective Study
POSTER: TCL-423 The Outcomes of Patients With T-Cell Prolymphocytic Leukemia After Allogenic Stem Cell Transplant: A Multicenter Retrospective Study Open
View article: TCL-423 The Outcomes of Patients With T-Cell Prolymphocytic Leukemia After Allogenic Stem Cell Transplant: A Multicenter Retrospective Study
TCL-423 The Outcomes of Patients With T-Cell Prolymphocytic Leukemia After Allogenic Stem Cell Transplant: A Multicenter Retrospective Study Open
View article: Atorvastatin for Anthracycline-Associated Cardiac Dysfunction
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction Open
Importance Anthracyclines treat a broad range of cancers. Basic and retrospective clinical data have suggested that use of atorvastatin may be associated with a reduction in cardiac dysfunction due to anthracycline use. Objective To test w…
View article: P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY
P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas, with a poor prognosis and a shortened survival for relapsed or refractory (R/R) disease. …
View article: P1182: A PROSPECTIVE STUDY OF TCR MEASURABLE RESIDUAL DISEASE IN PERIPHERAL T-CELL LYMPHOMA
P1182: A PROSPECTIVE STUDY OF TCR MEASURABLE RESIDUAL DISEASE IN PERIPHERAL T-CELL LYMPHOMA Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Peripheral T-Cell Lymphoma (PTCL) is an aggressive rare subset (~10-15%) of non-Hodgkin lymphomas. PTCL treatment often starts with anthracycline based chemotherapy and then…
View article: Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors Open
Not available.
View article: A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma Open
Autologous stem cell transplantation (ASCT) is often used as consolidation for several subtypes of peripheral T-cell lymphoma (PTCL) in first remission. However, many patients relapse after ASCT and have a very poor prognosis. There are no…